Future Oncology

简称 FUTURE ONCOL ·ENGLAND ·出版周期 Monthly ·年均收录 192 篇

2.6

最新影响因子

2.50%

自引率

投稿难度

偏慢,4-8周

审稿周期

期刊简介

Future Oncology是一本国际同行评审期刊，ISSN号为1479-6694，由英国Future Medicine Ltd出版，出版地为英国，出版周期为月刊。该杂志的影响因子根据年份有所不同，最新数据需查阅Journal Citation Reports。它属于非开放获取（非OA）期刊，被SCI收录，中科院分区情况需参考最新分区表。杂志专注于肿瘤学领域的前沿研究，涵盖肿瘤生物学、临床治疗、转化医学和个性化医疗等方向，尤其关注新兴疗法和肿瘤治疗的未来发展趋势。其发文特点包括发表原创研究、综述和专家观点，注重多学科交叉研究。杂志质量较高，审稿流程严格，但需注意其影响因子波动可能反映竞争激烈的肿瘤学领域动态，投稿前建议核实最新学术评价和分区信息以规避潜在风险。

影响因子趋势

近期发表

Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis 2026-09-19

MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis 2026-09-18

A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma 2026-09-17

Re: prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer 2026-09-16

Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma 2026-09-16

Plain language summary of the KRYSTAL-12 study results: adagrasib for non−small cell lung cancer with KRAS <sup>G12C</sup> mutations 2026-09-16

Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma 2026-09-12

Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2− metastatic breast cancer in Japan 2026-09-11

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma 2026-09-10

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions 2026-09-09